首页 | 官方网站   微博 | 高级检索  
     

艾迪注射液联合化疗治疗晚期非小细胞肺癌
引用本文:王天武.艾迪注射液联合化疗治疗晚期非小细胞肺癌[J].中国实验方剂学杂志,2011,17(18):261-263.
作者姓名:王天武
作者单位:贵州省毕节地区医院肿瘤科,贵州毕节,551700
摘    要:目的:观察艾迪注射液联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:将符合纳入标准的98例NSCLC患者随机分为观察组与对照组各49例。两组均给予TP化疗方案:TAX(多西他赛)65 mg/m2,gtt,30~60 min,d0;DDP(顺铂)25~30 mg/m2,gtt,d1~d3。观察组同时以艾迪注射液80~100 mL,加入0.9%生理盐水400 mL gtt,共14 d。两组均以3周为1个治疗周期,2个治疗周期后评价临床疗效及患者生存期及副反应发生情况。结果:观察组总有效率71.43%,对照组57.14%,两组差异显著(P<0.05)。观察组生存质量提高较对照组显著(P<0.05)。观察组CD3+,CD4+,CD4+/CD8+,NK细胞等治疗前后相比差异显著(P<0.05);CD4+,CD4+/CD8+,NK细胞治疗后两组差异有统计学意义(P<0.05)。两组骨髓毒性反应、外周神经毒性反应、呕吐等毒副反应均有统计学差异(P<0.05)。结论:艾迪注射液联合化疗治疗NSCLC临床疗效显著,可提高患者生活质量,提高免疫力,减少化疗引起的毒副反应。

关 键 词:非小细胞肺癌  艾迪注射液  化疗
收稿时间:2011/5/24 0:00:00

Aidi Injection Combined with Chemotherapy for the Treatment of Advanced Non-small Cell Lung Cancer
WANG Tian-wu.Aidi Injection Combined with Chemotherapy for the Treatment of Advanced Non-small Cell Lung Cancer[J].China Journal of Experimental Traditional Medical Formulae,2011,17(18):261-263.
Authors:WANG Tian-wu
Affiliation:The Department of Oncology, Bijie Cancer Hospital, Bijie 551700, China
Abstract:Objective: To observe the Aidi injection combined with chemotherapy for the treatment of advanced non-small cell lung cancer(NSCLC) clinically. Method: Based on inclusion criteria, 98 cases of NSCLC were randomly divided into observation group and the control group (n=49 each). Two groups were given TP chemotherapy:TAX (docetaxel) 65 mg/m2, gtt 30-60 min, d0; DDP(cisplatin) 25-30 mg/m2, gtt, d1-d3.While the observation group was treated with Aidi injection 80~100 mL, adding 0.9% saline 400 mL gtt, a total of 14 d. Three weeks for both groups were lasted as a treatment cycle, 2 treatment cycles were used to evaluate the clinical efficacy and survival in patients with and without the occurrence of side effects. Result: The total effective rate was 91.84%, 77.55% in the two groups with significant difference (P<0.05). The quality of life in the observation group was higher compared with that in the control group significantly(P<0.05).CD3+,CD4+,CD4+ /CD8+, NK cells observed before and after treatment the difference was significant(P<0.05); CD4+,CD4+/CD8+, NK cells after treatment between the two groups was statistically significant(P<0.05).Two groups in bone marrow toxicity, peripheral neurotoxicity, vomiting and other side effects were statistically different(P<0.05). Conclusion: Aidi injection combined with chemotherapy in the treatment of clinical NSCLC shows significant effect. It can improve the quality of life, enhance immunity, reduce the chemotherapy-induced toxicity.
Keywords:non-small cell lung cancer  Aidi injection  chemotherapy
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号